Background: Cancer-related cognitive impairment (CRCI) is often related to chemotherapy. Increased chronic inflammation is believed to play a key role in the development of CRCI related to chemotherapy but studies assessing this hypothesis specifically in patients receiving chemotherapy are rare. Methods: We assessed several cognitive domains using the Cambridge Neuropsychological Test Automated Battery (CANTAB) in twenty-two breast cancer patients currently receiving chemotherapy. We also measured inflammatory cytokine and receptor (MCP-1, TNF-α, sTNFRI, sTNFRII) concentrations in patient sera using Luminex assays. These concentrations were log-transformed to obtain a normal distribution. Associations between log-transformed cytokines and cognition were evaluated using Pearson correlations and linear regression, taking into account relevant covariates. Results: Increased concentrations of sTNFRI and sTNFRII were associated with poorer performance on the CANTAB Delayed Matching to Sample (DMS, tests visual memory). Increasing sTNFRI levels were negatively correlated with DMS percent correct (r = −0.47, p = 0.029) and DMS percent correct after a 12 second (s) delay (r = −0.65, p = 0.001). Increasing levels of sTNFRII negatively correlated with DMS percent correct after 12 s delay (r = −0.57, p = 0.006). After controlling for relevant demographic (i.e. age, education) and clinical variables (i.e. disease stage, regimen type), we found that increased sTNFRI remained significantly related to decline on the DMS at the 12 s delay (p = 0.018).
A B S T R A C T
Background: Cancer-related cognitive impairment (CRCI) is often related to chemotherapy. Increased chronic inflammation is believed to play a key role in the development of CRCI related to chemotherapy but studies assessing this hypothesis specifically in patients receiving chemotherapy are rare. Methods: We assessed several cognitive domains using the Cambridge Neuropsychological Test Automated Battery (CANTAB) in twenty-two breast cancer patients currently receiving chemotherapy. We also measured inflammatory cytokine and receptor (MCP-1, TNF-α, sTNFRI, sTNFRII) concentrations in patient sera using Luminex assays. These concentrations were log-transformed to obtain a normal distribution. Associations between log-transformed cytokines and cognition were evaluated using Pearson correlations and linear regression, taking into account relevant covariates. Results: Increased concentrations of sTNFRI and sTNFRII were associated with poorer performance on the CANTAB Delayed Matching to Sample (DMS, tests visual memory). Increasing sTNFRI levels were negatively correlated with DMS percent correct (r = −0.47, p = 0.029) and DMS percent correct after a 12 second (s) delay (r = −0.65, p = 0.001). Increasing levels of sTNFRII negatively correlated with DMS percent correct after 12 s delay (r = −0.57, p = 0.006). After controlling for relevant demographic (i.e. age, education) and clinical variables (i.e. disease stage, regimen type), we found that increased sTNFRI remained significantly related to decline on the DMS at the 12 s delay (p = 0.018).
Conclusion: This preliminary study shows a significant association between higher sTNFRI and lower scores on the short-term visual memory delayed match to sample test in breast cancer patients receiving chemotherapy, supporting the hypothesis that sTNFRI is involved in CRCI.
Introduction
Cancer-related cognitive impairment (CRCI) involves impairments in cognitive domains of memory, attention, executive functioning, and processing speed (reviewed in Wefel et al., 2015) . CRCI has been reported to have a significant impact on quality of life, disrupting daily functioning as well as self-esteem, self-confidence, and perceived work ability of cancer survivors (Reid-Ardnt et al., 2009 , Wefel et al., 2004 , Von et al., 2013 . While CRCI is likely to have a complex etiology, chemotherapy is most likely to initiate and exacerbate these problems with up to 75% of patients reporting some kind of impairment during these treatments (reviewed in Janelsins et al., 2014 , Janelsins et al., 2016 . Several prospective longitudinal studies evaluating cognitive function prior to and up to one year after chemotherapy have reported
